AFGHANISTAN
CERVICAL CANCER PROFILE

Morbidity and Mortality

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crude cervical cancer incidence per 100 000 women (2020)</td>
<td>6.3</td>
</tr>
<tr>
<td>Age-standardized cervical cancer incidence per 100 000 women</td>
<td>10.4</td>
</tr>
<tr>
<td>Cumulative risk of cervical cancer, ages 0-74 (2020)</td>
<td>1.1%</td>
</tr>
<tr>
<td>Cervical cancer deaths (2019)</td>
<td>540</td>
</tr>
<tr>
<td>Cervical cancer mortality-to-incidence ratio (2020)</td>
<td>0.69</td>
</tr>
<tr>
<td>Population-based cancer registry exists (2021)</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Primary Prevention

HPV vaccination programme coverage among girls (2020)

- Programme coverage:
  - no data
- Coverage by age 15:
  - no data

HPV vaccination programme (2020):

- HPV included in national vaccination programme: No
- Scale of vaccination programme: -
- Year of introduction: -
- Primary target cohort: -

Related risk factors:

- Tobacco use prevalence, women aged 15+ years (2020): 6%
- Condom use at last high-risk sex (-): ND
- HIV incidence per 1000, women aged 15+ years (2020): 0.04

Secondary Prevention

National screening programme for cervical cancer exists (2021): No
- Primary screening test used (2021): -
- Target age range of programme (2021): -
- Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021): No
- Clearly defined referral system exists from primary care to secondary and tertiary care (2021): No

Treatment and Supportive Care

National guidelines on cervical cancer management exist (2021): No

Cancer diagnosis and treatment services generally available (2021):

- Cancer centre or cancer department at tertiary level: Yes
- Pathology services (laboratories): Yes
- Cancer surgery: Yes
- Chemotherapy: Yes
- Radiotherapy: Yes

Palliative care for patients with NCDs in the public health system generally available (2021):

- In primary health care facilities: No
- In community or home-based care: No

WHO Cervical Cancer Elimination Strategy Targets for 2030

- 90% of girls fully vaccinated with the HPV vaccine by the age of 15
- 70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age
- 90% of women identified with cervical disease receive treatment

ND = data not available

* Programme coverage: % of national target population (among 9-14-year-old girls)
† Coverage by age 15: % of population turning 15 that have been vaccinated against HPV at any time between ages 9 to 14

See Explanatory Notes for indicator descriptions.